Efficacy of systemic therapy in advanced pancreatic carcinoma

Acta Oncologica

Volumn 45, Issue 2, 2006, Pages 136-143

  Lideståhl, Anders ^a,b   Permert, Johan ^a   Linder, Stefan ^b   Bylund, Håkan ^b   Edsborg, Nick ^a   Lind, Pehr ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BEVACIZUMAB; CAPECITABINE; CARMUSTINE; CISPLATIN; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; G17DT ANTIGEN; GEMCITABINE; IRINOTECAN; LOMUSTINE; MARIMASTAT; OXALIPLATIN; PEMETREXED; TIPIFARNIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; HUMANS; PANCREATIC NEOPLASMS; QUALITY OF LIFE;

EID: 33645100097     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500537861     Document Type: Review

References (52)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-66.
2. Andren-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the new millennium. Pancreatology 2002;2(5):431-9.
3. Permert J, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001;40(2-3):361-70.
4. Andersen JR, Friis-Moller A, Hancke S, Roder O, Steen J, Baden H. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol 1981;16(8):973-5.
5. Andren-Sandberg A, Holmberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. Scand J Gastroenterol 1983;18(5):609-12.
6. Frey C, Twomey P, Keehn R, Elliott D, Higgins G. Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981;47(1):27-31.
7. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7(6):593-600.
8. Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980;281(6255):1589-91.
9. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81(6):882-5.
10. Fung MC, Ishiguro H, Takayama S, Moriazane T, Adachi S, Sakata T. Survival benefit of chemotherapy treatment in advanced pancreatic cancer: A metaanalysis. Proc Am Soc Clin Oncol 2003;22:288 (abstract 1155).
11. Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986;57(1):29-33.
12. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol 1986;4(12):1794-8.
13. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992;70(7):1864-6.
14. Marsh RW, Manyam V, Bewsher C, Youngblood M. Circadian rhythm modulated 5-FUdR infusion with Megace in the treatment of advanced pancreatic cancer. J Surg Oncol 1994;57(1):25-9.
15. Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9(9):1682-6.
16. Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988;6(6):1053-8.
17. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991;9(12):2128-33.
18. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13.
19. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73(1):101-5.
20. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12(1):29-34.
21. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85(6):1261-8.
22. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21(18):3402-8.
23. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc Am Soc Clin Oncol 2005 (LBA 4013).
24. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94(4):902-10.
25. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. (Abstract 1003). Proc Am Soc Clin Oncol 2003;22:250.
26. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20(15):3270-5.
27. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. Gemcitabine alone in patients with advanced pancreatic cancer. Proc Soc Am Clin Oncol 2005 (abstract 4009).
28. Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study. Ann Oncol 2003;14(4):580-5.
29. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20(6):1512-8.
30. Louvet C, Labianca R, Hammel P, Lledo G, De Baud F, Andre T, et al. GemOx (gemcitabine+oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR /GISCAD Intergroup Phase III. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting edition) 2004;22(14S): 4008.
31. Rocha Lima CM, Green MR, Rotche R, Miller WJ, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22(18):3776-83.
32. Stathopoulos G, Aravantinos G, Syrigos K, Kalbakis K, Karvounis N, Papakotoulas P, et al. A randomized phase III study of Irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005 (abstract 4106).
33. Richards DA, Kindler HL, Oettle H, Ramanthan R, Van Laethem J-L, Peeters M, et al. A randomized phase III study comparing gemcitabine +pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S):4007.
34. O Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano MR, Hurwitz H, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S):4006.
35. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6(6):369-76.
36. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 2005 (abstract 4010).
37. Nygren P, Halfdan S, Österlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
38. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87(2):161-7.
39. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22(8):1430-8.
40. Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005 Gastrointestinal Cancers Symposium (abstract 77).
41. Kindler HL, Friberg G, Stadler WM, Singh DA, Locker G, Nattam S, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S):4009.
42. Shapiro J, Marshall J, Karasek P, Figer A, Oettle H, Couture F, et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study. Proc Am Soc Clin Oncol 2005 (abstract 4012).
43. Gilliam AD, Topuzov EG, Garin AM, Pulay I, Broome P, Watson A, et al. Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S (July 15 Supplement)).
44. Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002;20(20):4225-31.
45. Lideståhl A, Permert J, Linder S, Bylund H, Edsborg N, Lind P. Reassessment for radical surgery after palliative chemotherapy in locally advanced pancreatic carcinoma: Two case reports. Letter to the Editor; Acta Oncol; 2005; in press.
46. Starkhammar H. Aspects on priority settings in cancer treatment and care. Acta Oncol; 2005; in press.
47. Ferdinandi ES, Braun DP, Liu C, Zee BC, Ely G. Virulizin(R)-A review of its antineoplastic activity. Expert Opin Investig Drugs 1999;8(10):1721-35.
48. Morello E, Dernell WS, Kuntz CA, LaRue SM, Lafferty M, Nelson A, et al. Evaluation of cisplatin in combination with a biologic response modifier in a murine mammary carcinoma model. Cancer Invest 2002;20(4):480-9.
49. Feng N, Jin H, Wang M, Du C, Wright JA, Young AH. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemother Pharmacol 2003;51(3):247-55.
50. Du C, Feng N, Jin H, Wang M, Wright JA, Young AH. Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models. Anticancer Drugs 2003;14(4):289-94.
51. Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, et al. Macrophages play a critical role in the anti-tumor activity of Virulizin. Int J Oncol 2003;23(5):1341-6.
52. Cunningham D, Chau I, Stocken C, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolomeos J. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005;3(4) (Suppl):S4, Abstract PS11.